Use of Immune Checkpoint Inhibitors in Refractory Mycosis Fungoides and Sézary Syndrome: A Systematic Review

Mycosis fungoides (MF) and Sezary syndrome (SS) are cutaneous T cell lymphomas, and represent the most common cutaneous lymphoma and an aggressive leukemic variant of cutaneous lymphomas respectively. MF is characterized by granulomatous slack skin with distinct clinical and histological findings and SS is characterized by lymphadenopathy, erythroderma, and often peripheral malignant cell hematological findings. While immunosuppressive therapies are often geared towards symptom relief in these conditions, adverse exacerbation of malignancy may occur. This review investigates the response and safety of immune checkpoint inhibition in refractory MF and SS.